Injectable compositions for the controlled delivery of pharmacologically active compound 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
EP1446103 A2 2004-08-18 [EP1446103]EP1446103 A4 2011-01-12 [EP1446103]EP1446103 B1 2015-12-23 [EP1446103] / 2004-08-182011-01-122015-12-23
申请号/申请日
2002EP-0802160 / 2002-10-18
发明人
MURTHY YERRAMILLI V S N;SUVA ROBERT;
申请人
IDEXX LABORATORIES;
主分类号
IPC分类号
A01N-037/18A61K-009/00A61K-009/08A61K-009/10A61K-031/137A61K-031/138A61K-031/165A61K-031/18A61K-031/24A61K-031/245A61K-031/4704A61K-031/496A61K-031/505A61K-031/65A61K-031/7034A61K-031/7036A61K-031/7048A61K-047/10A61K-047/12A61K-047/14A
摘要
(EP1446103) The present invention provides compositions and methods for extending the release times and lowering the toxicity of pharmacologically active compounds.  The compounds comprise a salt of the pharmacologically active compound with a lipophilic counterion and a pharmaceutically acceptable water soluble solvent combined together to form an injectable composition.  The lipophilic counterion may be a saturated or unsaturated C8-C22 fatty acid, and preferably may be a saturated or unsaturated C10-C18 fatty acid.  When injected into a mammal, at least a portion of the composition precipitates and releases the active compound over time.  Thus, the composition forms a slowly releasing drug depot of the active compound in the mammal.  Therefore, the present invention enables one to provide a controlled dose administration of the active compound for a periods of up to 15 days or even longer.  Many compounds can be administered according to the present invention including, but not limited to, tilmicosin, oxytetracycline, metoprolol, fluoxetine, roxithromycin, and turbinafine.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2001US-60343625 2001-10-19 2002WO-US33300 2002-10-18
主权利要求
(EP1446103) 1. A composition for administration of a pharmacologically active compound to a mammal comprising  a salt of a basic pharmacologically active compound and a lipophilic acid wherein the lipophilic acid is selected from the group consisting of saturated or unsaturated fatty acids, cholic acids, phospatidic acids, dicarboxylic acids (like sebacic acid), polysebacic acid and polybenzoic acid; and  a pharmaceutically acceptable organic solvent, wherein the pharmaceutically acceptable solvent is selected from the group consisting of one or a combination of: pyrrolidone, N-methyl pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbide dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, and triacetin;  combined together to form an injectable composition,  wherein the composition forms a precipitate when the composition is introduced or injected into an aqueous environment and  wherein the composition releases the active compound over time when introduced or injected into the aqueous environment. 2. The composition of claim 1 wherein the pharmaceutically acceptable solvent is a water miscible solvent. 3. The composition of claim 1 wherein the pharmacologically active compound is an antibiotic. 4. The composition of claim 1 wherein the pharmacologically active compound is tilmicosin, oxytetracycline, doxycycline, fluoxetine, roxithromycin, turbinafine or metoprolol. 5. The composition of claim 1 wherein the pharmacologically active compound is selected from the group consisting of: trimethoprim, neomycin, streptomycin, gentamycin, dibucaine, bupivacaine, benzocaine, tetracaine, acepromazine, itraconazole, tetracyclines, sulfonamides, and aminoglycosides. 6. The composition of claim 1 wherein the lipophilic acid is a C 10-C 22 saturated or un-saturated fatty acid. 7. The composition of claim 1 wherein the lipophilic acid is a C 10-C 18 saturated or unsaturated fatty acid. 8. The composition of claim 7 wherein the fatty acid is selected from the group consisting of: lauric acid, decanoic acid, myristic acid, oleic acid and linoleic acid. 9. The composition of claim 1 wherein the pharmaceutically acceptable solvent comprises 10% propylene glycol in glycerol formal with or without stabilizers. 10. The composition of claim 1 wherein the pharmaceutically acceptable solvent is triacetin. 11. The composition of claim 1 wherein the pharmacologically active compound is oxytetracycline, the lipophilic acid is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 12. The composition of claim 1 wherein the pharmacologically active compound is tilmicosin, the lipophilic acid is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 13. A pharmacologically active composition comprising a salt of a basic pharmacologically active compound and a lipophilic acid, selected from the group consisting of saturated or unsaturated fatty acids, cholic acids, phosphatidic acids, and dicarboxylic acids; and a pharmaceutically acceptable organic solvent wherein the pharmaceutically acceptable solvent is selected from the group consisting of one or a combination of: pyrrolidone, N-methyl pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbide dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, and triacetin;  combined together to form an injectable composition for use in treating a condition in a mammal that is responsive to the pharmacologically active compound; wherein the composition forms a precipitate and releases the active compound over time when injected into the mammal. 14. The pharmacologically active composition for use of claim 13 wherein the pharmaceutically acceptable solvent is a water miscible solvent. 15. The pharmacologically active composition for use of claim 13 wherein the pharmacologically active compound is an antibiotic. 16. The pharmacologically active composition for use of claim 15 wherein the antibiotic is tilmicosin, tetracycline, or doxycycline. 17. The pharmacologically active composition for use of claim 15 wherein the antibiotic is selected from the group consisting of: trimethoprim, neomycin, streptomycin, gentamycin, tetracyclines, sulfonamides, and aminoglycosides. 18. The pharmacologically active composition for use of claim 13 wherein the lipophilic counterion is a fatty acid. 19. The pharmacologically active composition for use of claim 18 wherein the fatty acid is a C 10-C 22 fatty acid. 20. The pharmacologically active composition of for use claim 19 wherein the fatty acid is selected from the group consisting of: lauric acid, decanoic acid, myristic acid, oleic acid and linoleic acid. 21. The pharmacologically active composition for use of claim 13 wherein the lipophilic counterion is sebacic acid. 22. The pharmacologically active composition for use of claim 13 wherein the pharmaceutically acceptable carrier is triacetin. 23. The pharmacologically active composition for use of claim 13 wherein the pharmacologically active compound is oxytetracycline, the lipophilic counterion is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 24. The pharmacologically active composition for use of claim 13 wherein pharmacologically active compound is tilmicosin, the lipophilic counterion is decanoic acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 25. A method of manufacturing an injectable formulation for the administration of a pharmacologically active compound to a mammal comprising: providing a salt of a basic pharmacologically active compound and a lipophilic acid wherein the lipophilic acid is selected from the group consisting of saturated or unsaturated fatty acids, cholic acids, phospatidic acids, and dicarboxylic acids; and providing a pharmaceutically acceptable organic solvent wherein the pharmaceutically acceptable solvent is selected from the group consisting of one or a combination of: pyrrolidone, N-methyl pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbide dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, and triacetin; combining together the salt and the pharmacologically acceptable organic solvent to provide an injectable composition, wherein the composition forms a precipitate when the composition is introduced or injected into an aqueous environment and wherein the composition releases the active compound over time when introduced or injected into the aqueous environment. 26. The method of claim 25 wherein the pharmaceutically acceptable solvent is a water miscible solvent. 27. The method of claim 25 wherein the pharmacologically active compound is an antibiotic. 28. The method of claim 27 wherein the antibiotic is tilmicosin, tetracycline, or doxycycline. 29. The method of claim 27 wherein the antibiotic is selected from the group consisting of: trimethoprim, neomycin, streptomycin, gentamycin, tetracyclines, sulfonamides, and aminoglycosides. 30. The method of claim 25 wherein the lipophilic acid is a C 8-C 22 fatty acid. 31. The method of claim 30 wherein the fatty acid is a C 10-C 22 fatty acid. 32. The method of claim 31 wherein the fatty acid is selected from the group consisting of: lauric acid, decanoic acid, myristic acid, oleic acid and linoleic acid. 33. The method of claim 25 wherein the lipophilic acid is sebacic acid. 34. The method of claim 25 wherein the pharmaceutically acceptable carrier is triacetin. 35. The method of claim 25 wherein the pharmacologically active compound is oxytetracycline, the lipophilic acid is lauric acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 36. The method of claim 25 wherein the pharmacologically active compound is tilmicosin, the lipophilic acid is decanoic acid, and the pharmaceutically acceptable solvent is selected from the group consisting of one or more of polyethylene glycol, propylene glycol, and glycerol formal. 37. The method of claim 30 wherein the fatty acid is a C 10-C 18 fatty acid.
法律状态
(EP1446103) LEGAL DETAILS FOR EP1446103  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED     Event publication date=2002-10-18  Event code=EP/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=EP EP02802160  Application date=2002-10-18  Standardized application number=2002EP-0802160     Event publication date=2004-08-18  Event code=EP/A2  Event type=Examination events  Application published without search report  Publication country=EP  Publication number=EP1446103  Publication stage Code=A2  Publication date=2004-08-18  Standardized publication number=EP1446103     Event publication date=2004-08-18  Event code=EP/17P  Event indicator=Pos  Event type=Examination events  Request for examination filed Pruefungsantrag gestellt  Effective date of the event=2004-05-18     Event publication date=2004-08-18  Event code=EP/AK  Event indicator=Pos  Event type=Designated states  Designated contracting states: Benannte vertragsstaaten AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR    Event publication date=2004-08-18  Event code=EP/AX  Event indicator=Pos  Event type=Designated states  Extension of the European patent to Request for extension of the european patent to AL LT LV MK RO SI    Event publication date=2011-01-12  Event code=EP/A4  Event indicator=Pos  Event type=Examination events  Supplementary search report Ergaenzender recherchenbericht  Publication country=EP  Publication number=EP1446103  Publication stage Code=A4  Publication date=2011-01-12  Standardized publication number=EP1446103     Event publication date=2011-01-12  Event code=EP/A4  Event indicator=Pos  Event type=Administrative notifications  Supplementary search report Despatch of supplementary search report  Effective date of the event=2010-12-13     Event publication date=2011-12-21  Event code=EP/17Q  Event indicator=Pos  Event type=Examination events  First examination report Erster pruefungsbescheid  Effective date of the event=2011-11-17     Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  47/20        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  47/10        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  31/7034      20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  47/12        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  31/7048      20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  31/24        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  31/65        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  47/22        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A01N  37/18        20060101AFI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  47/26        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  47/14        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K   9/08        20060101ALI20150529BHEP    Event publication date=2015-07-08  Event code=EP/RIC1  Event type=Classification modifications  Event type=Corrections  Classification (correction) IPC: A61K  31/496       20060101ALI20150529BHEP    Event publication date=2015-07-29  Event code=EP/INTG  Event indicator=Pos  Event type=Examination events  Announcement of intention to grant  Effective date of the event=2015-06-30     Event publication date=2015-12-02  Event code=EP/RIN1  Event type=Change of name or address  Event type=Administrative notifications  Inventor (correction) Inventor changed before grant    Event publication date=2015-12-02  Event code=EP/RIN1  Event type=Change of name or address  Event type=Administrative notifications  Inventor (correction) Inventor changed before grant    Event publication date=2015-12-23  Event code=EP/B1  Event indicator=Pos  Event type=Event indicating In Force  Patent specification  Publication country=EP  Publication number=EP1446103  Publication stage Code=B1  Publication date=2015-12-23  Standardized publication number=EP1446103     Event publication date=2015-12-23  Event code=EP/AK  Event indicator=Pos  Event type=Designated states  Designated contracting states: Benannte vertragsstaaten AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR    Event publication date=2016-11-30  Event code=EP/26N  Event indicator=Pos  Event type=No opposition filed  Event type=Event indicating In Force  No opposition filed Kein einspruch eingelegt  Effective date of the event=2016-09-26  MEMBER STATE LEGAL DETAILS FOR AT  Actual or expected expiration date=2015-12-23    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=AT Corresponding appl: AT766101    Event publication date=2016-01-15  Event code=EP/REG  Event code=AT/REF  Event indicator=Pos  Event type=Entry into national phase  Reference to a national code Reference to at number (ep patent enters austrian national phase) Nennung der e-nummer (ep patent tritt in at nationale phase ein) Corresponding cc:  Designated or member state=AT   Effective date of the event=2016-01-15     Event publication date=2016-05-15  Event code=EP/REG  Event code=AT/MK05  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Revocation of the translation of the ep patent Loeschung gemaess par. 5 (zurueckziehung der uebersetzung des ep patents) Corresponding cc:  Designated or member state=AT   Effective date of the event=2015-12-23     Event publication date=2016-08-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=AT  MEMBER STATE LEGAL DETAILS FOR BE  Actual or expected expiration date=2016-12-30    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=BE     Event publication date=2016-12-30  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=BE  MEMBER STATE LEGAL DETAILS FOR BG  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=BG     Event publication date=2017-10-26  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2017-10-26     Year of payment of annual fees=16  Corresponding cc:  Designated or member state=BG  MEMBER STATE LEGAL DETAILS FOR CH  Actual or expected expiration date=2017-05-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=CH     Event publication date=2015-12-31  Event code=EP/REG  Event code=CH/EP  Event indicator=Pos  Event type=Entry into national phase  Reference to a national code Entry in the national phase Eintritt in die nationale phase Corresponding cc:  Designated or member state=CH     Event publication date=2017-05-31  Event code=EP/REG  Event code=CH/PL  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Patent ceased Loeschung/radiation/radiazion Corresponding cc:  Designated or member state=CH     Event publication date=2017-07-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES  Corresponding cc:  Designated or member state=CH  MEMBER STATE LEGAL DETAILS FOR CZ  Actual or expected expiration date=2016-07-29    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=CZ     Event publication date=2016-07-29  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=CZ  MEMBER STATE LEGAL DETAILS FOR DE  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=DE Corresponding appl: DE60247691    Event publication date=2015-05-29  Event code=EP/REG  Event code=DE/R079  Event type=Examination events  Reference to a national code Amendment of ipc main class Aenderung der IPC hauptklasse IPC: A01N0037180000    Event publication date=2015-05-29  Event code=EP/REG  Event code=DE/R079  Event type=Examination events  Reference to a national code Amendment of ipc main class Aenderung der IPC hauptklasse Corresponding cc:  Designated or member state=DE  PREVIOUS MAIN CLASS: A61K0009000000     Event publication date=2016-01-28  Event code=EP/REG  Event code=DE/R096  Event indicator=Pos  Event type=Examination events  Reference to a national code DPMA publication of mentioned EP patent grant Veroeffentlichung eines hinweises auf die ep-patenterteilung durch das dpma Corresponding cc:  Designated or member state=DE     Event publication date=2016-09-26  Event code=EP/REG  Event code=DE/R097  Event indicator=Pos  Event type=No opposition filed  Reference to a national code No opposition filed against granted patent, or EPO opposition proceedings concluded without decision Gegen die patenterteilung wurde kein einspruch erhoben, bzw. einspruchsverfahren ist beim epa ohne entscheidung abgeschlossen Corresponding cc:  Designated or member state=DE     Event publication date=2017-10-27  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2017-10-27     Year of payment of annual fees=16  Corresponding cc:  Designated or member state=DE  MEMBER STATE LEGAL DETAILS FOR DK  Actual or expected expiration date=2016-10-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DK     Event publication date=2016-10-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=DK  MEMBER STATE LEGAL DETAILS FOR EE  Actual or expected expiration date=2016-08-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=EE     Event publication date=2016-08-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=EE  MEMBER STATE LEGAL DETAILS FOR ES2561108  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=ES Corresponding appl: ES02802160  Application date in the designated or member state=2002-10-18   Application number in the designated or member state=2002ES-0802160T Corresponding cc:  Designated or member state=ES Corresponding pat: ES2561108  Publication stage code in the designated or member state=T3  Publication date in the designated or member state=2016-02-24   Publication number in the designated or member state=ES2561108    Event publication date=2016-02-24  Event code=EP/REG  Event code=ES/FG2A  Event indicator=Pos  Event type=Event indicating In Force  Reference to a national code Definitive protection Proteccion definitiva Corresponding cc:  Designated or member state=ES   Effective date of the event=2016-02-24     Event publication date=2017-11-02  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2017-11-02     Year of payment of annual fees=16  Corresponding cc:  Designated or member state=ES  MEMBER STATE LEGAL DETAILS FOR FI  Actual or expected expiration date=2016-05-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=FI     Event publication date=2016-05-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=FI  MEMBER STATE LEGAL DETAILS FOR FR  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=FR     Event publication date=2016-10-25  Event code=EP/REG  Event code=FR/PLFP  Event indicator=Pos  Event type=Payment or non-payment notifications  Event type=Restitution or restoration  Reference to a national code Fee payment Derniere annuite payee   Annual fees payment date=2016-10-25     Year of payment of annual fees=15  Corresponding cc:  Designated or member state=FR     Event publication date=2017-10-25  Event code=EP/REG  Event code=FR/PLFP  Event indicator=Pos  Event type=Payment or non-payment notifications  Event type=Restitution or restoration  Reference to a national code Fee payment Derniere annuite payee   Annual fees payment date=2017-10-25     Year of payment of annual fees=16  Corresponding cc:  Designated or member state=FR     Event publication date=2017-10-25  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2017-10-25     Year of payment of annual fees=16  Corresponding cc:  Designated or member state=FR  MEMBER STATE LEGAL DETAILS FOR GB  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=GB     Event publication date=2015-12-23  Event code=EP/REG  Event code=GB/FG4D  Event indicator=Pos  Event type=Event indicating In Force  Reference to a national code European patent granted Corresponding cc:  Designated or member state=GB     Event publication date=2017-10-27  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2017-10-27     Year of payment of annual fees=16  Corresponding cc:  Designated or member state=GB  MEMBER STATE LEGAL DETAILS FOR GR  Actual or expected expiration date=2016-05-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=GR     Event publication date=2016-05-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=GR  MEMBER STATE LEGAL DETAILS FOR IE  Actual or expected expiration date=2017-07-26    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=IE     Event publication date=2016-01-13  Event code=EP/REG  Event code=IE/FG4D  Event indicator=Pos  Event type=Event indicating In Force  Reference to a national code European patents granted designating ireland Corresponding cc:  Designated or member state=IE     Event publication date=2017-07-26  Event code=EP/REG  Event code=IE/MM4A  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Patent lapsed Corresponding cc:  Designated or member state=IE     Event publication date=2017-11-30  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES  Corresponding cc:  Designated or member state=IE  MEMBER STATE LEGAL DETAILS FOR IT  Actual or expected expiration date=2022-10-18    Legal state=ALIVE    Status=GRANTED   Corresponding cc:  Designated or member state=IT     Event publication date=2017-10-24  Event code=EP/PGFP  Event indicator=Pos  Event type=Event indicating In Force  Event type=Payment or non-payment notifications  Postgrant: annual fees paid to national office   Annual fees payment date=2017-10-24     Year of payment of annual fees=16  Corresponding cc:  Designated or member state=IT  MEMBER STATE LEGAL DETAILS FOR LI  Actual or expected expiration date=2017-07-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=LI     Event publication date=2017-07-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES  Corresponding cc:  Designated or member state=LI  MEMBER STATE LEGAL DETAILS FOR LU  Actual or expected expiration date=2017-08-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=LU     Event publication date=2017-08-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES  Corresponding cc:  Designated or member state=LU  MEMBER STATE LEGAL DETAILS FOR NL  Actual or expected expiration date=2015-12-23    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=NL     Event publication date=2016-04-28  Event code=EP/REG  Event code=NL/MP  Event indicator=Neg  Event type=Event indicating Not In Force  Reference to a national code Patent voided (invalid in the netherlands as no translation has been filed) Corresponding cc:  Designated or member state=NL   Effective date of the event=2015-12-23     Event publication date=2016-05-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=NL  MEMBER STATE LEGAL DETAILS FOR PT  Actual or expected expiration date=2016-08-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=PT     Event publication date=2016-08-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=PT  MEMBER STATE LEGAL DETAILS FOR SE  Actual or expected expiration date=2016-05-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=SE     Event publication date=2016-05-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=SE  MEMBER STATE LEGAL DETAILS FOR SK  Actual or expected expiration date=2016-08-31    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=SK     Event publication date=2016-08-31  Event code=EP/PG25  Event indicator=Neg  Event type=Event indicating Not In Force  Event type=Payment or non-payment notifications  Lapsed in a contracting state announced via postgrant inform. from nat. office to EPO LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT  Corresponding cc:  Designated or member state=SK
专利类型码
A2A4B1
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部